Skip to main content
. 2017 Jun;10(4):165–174.

Table 2.

Patient Demographics Measured as of Index Date

Demographics Propensity score matched Unmatched
Patients using sulfonylurea (N = 13,657) Patients using SGLT-2 inhibitor (N = 13,657) Standardized difference for matched cohorts, % Patients using sulfonylurea (N = 25,490) Patients using SGLT-2 inhibitor (N = 17,724) P value for unmatched cohorts
Age, yrs, mean (SD) 54.3 (9.7) 54.3 (9.5) 0.522 57.7 (11.8) 54.0 (9.2) <.001
Age-group <.001
  18-34 yrs 2.6% 2.5% 0.880 2.1% 2.4%
  35-44 yrs 12.6% 12.6% 0.229 10.2% 12.8%
  45-54 yrs 32.9% 32.2% 1.528 26.0% 33.6%
  55-64 yrs 42.6% 42.8% 0.572 39.4% 42.8%
  65-79 yrs 8.7% 9.3% 2.109 17.2% 7.9%
  ≥80 yrs 0.6% 0.6% 0.692 5.0% 0.5%
Men 53.9% 53.4% 1.005 56.1% 52.9% <.001
Insurance plan type <.001
  Comprehensive 5.3% 5.4% 0.227 13.9% 4.5%
  EPO 0.5% 0.3% 2.691 0.4% 0.3%
  HMO 8.9% 8.9% 0.281 10.6% 8.4%
  POS 5.2% 5.1% 0.068 5.4% 5.1%
  PPO 60.2% 60.8% 1.078 53.1% 62.0%
  POS with capitation 0.4% 0.7% 3.647 0.3% 0.7%
  CDHP 11.0% 10.7% 0.813 8.7% 11.1%
  HDHP 3.7% 3.4% 1.556 3.3% 3.3%
  Unknown 4.9% 4.7% 0.909 4.3% 4.7%
Payer <.001
  Commercial 90.0% 89.7% 1.043 77.0% 91.2%
  Medicare 10.0% 10.3% 1.043 23.0% 8.8%
Geographic region <.001
  Northeast 17.0% 17.0% 0.125 16.3% 16.8%
  North Central 16.6% 16.9% 0.739 23.4% 15.8%
  South 58.3% 57.8% 1.143 49.7% 59.9%
  West 7.9% 8.2% 1.320 10.6% 7.5%
  Unknown 0.2% 0.1% 0.637 0.1% 0.1%
Population density .022
  Urban 83.7% 83.8% 0.344 83.3% 84.3%
  Rural 16.2% 16.1% 0.236 16.6% 15.7%
  Unknown 0.1% 0.1% 1.334 0.1% 0.1%
Index copay, mean (SD)a $4 ($6) $48 ($70) 88.163 $4 ($6) $48 ($83) <.001
a

Not used in the propensity score model.

CDHP indicates consumer-directed health plan; EPO, exclusive provider organization; HDHP, high-deductible health plan; HMO, health maintenance organization; POS, point of service; PPO, preferred provider organization; SD, standard deviation; SGLT-2, sodium-glucose cotransporter 2.